Published on 11 Feb 2022 on Zacks via Yahoo Finance
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
This week, Pfizer PFE, AstraZeneca AZN and Glaxo GSK announced fourth-quarter and full-year 2021 results. While the FDA approved Sanofi’s SNY new rare blood disorder medicine, Enjaymo, an FDA advisory committee, voted that Eli Lilly LLY and partner Innovent Biologics conduct an additional study to get approval for their lung cancer candidate, sintilimab, in the United States.
Recap of the Week’s Most Important Stories
Earnings Update: Pfizer’s fourth-quarter results were mixed as it beat estimates for earnings but missed the same for sales. Direct sales and alliance revenues from it and partner BioNTech’s COVID-19 vaccine, Comirnaty, were $12.5 billion in the quarter,